|

The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)

In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.

In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?

The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?

Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.

Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.

It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.

James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.

In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.

Enjoy the episode!

Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Cybin #Psilocybin #Psychedelics

Similar Posts

  • Can DMT Treat Depression?

    Welcome to the Psychedelic Spotlight podcast. In this episode, the Psychedelic Investor sits down with Dr. Carol Routledge, Chief Scientific and Chief Medical Officer of Small Pharma (TSX.V: DMT, OTC: DMTTF). Dr. Carol Routhledge is an expert in psychedelic medicines, and she specializes in DMT.

    In this interview, we attempted to answer the following questions:

    What happens when you take DMT?

    Can DMT help with depression?

    Is DMT safe?

    Small Pharma is a company that I am very excited about, as they are focussing on the psychedelic DMT, which I believe to have unlimited potential as a mental health drug.

    Small Pharma is currently running a phase 2 Clinical Trial Attempting to treat Major Depressive Disorder using DMT, the world’s furthest progress DMT Study. We can expect results by the end of the year. If they are successful, the company will begin a phase 3 trial.

    #DMT #SmallPharma #depression

  • Is Compass Pathways a GOOD INVESTMENT? (CMPS stock analysis)

    In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin.

    To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things:

    What problem is Compass Pathways trying to solve?
    CMPS’ clinical trial, treating depression with psilocybin
    The founders and leaders of Compass Pathways
    Compass’ Financials
    Is CMPS stock a good investment for a retail investor?

    As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity.
    Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021?

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    Resources:
    https://compasspathways.com/

    https://www.webmd.com/depression/understanding-depression-basics#1

    https://www.psychiatry.org/patients-families/depression/what-is-depression

    https://www.nimh.nih.gov/health/statistics/major-depression.shtml

    https://www.webmd.com/depression/guide/depression-treatment-options#1

    https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective

    https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1

    https://www.beckleyfoundation.org/psilocybin-for-depression-2

    https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows

    https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav

    https://psychedelicreview.com/person/ekaterina-malievskaia/

    https://compasspathways.com/team-member/george-goldsmith/
    https://compasspathways.com/team-member/lars-christian-wilde/

    https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T

    https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html

    https://www.treehugger.com/facts-about-magic-mushrooms-4868810
    https://psychedelicreview.com/person/ekaterina-malievskaia/

    #CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor

  • MORE Companies to UPLIST On NASDAQ? Compass Pathways Trial Results & More (CMPS, FTRP, MYCO, CYBN) 🚀

    Compass Pathways (CMPS:NASDAQ) published amazing COMP360 Psilocybin Study results that will serve as support for companies working with psilocybin and psilocybin derivatives. However, this isn’t the only news worth mentioning.
    Field Trip Health (FTRP: CSE) and (FTRPF: OTC) recently uplisted on the TSX ( Toronto Stock Exchange) and has filed an application to uplist on the Nasdaq.
    While this is great news for Field Trip, it is not the only company who has filed to uplist. Silo Pharma, (SILO: OTC), has also put in an application to list on NASDAQ.
    MagicMed will also join the ranks, however it will be through an acquisition.

    Moreover, Cybin (CYBN: NEO,) and (CLXPF: OTC), is working on a transportable, wearable, helmet that completes a brain scan, through a partnership with a company called Kernel.
    There is also news on Mydecine ( MYCO: NEO) and ( MYCOF: OTC) and MindCure (CSE: MCUR) (OTCQB: MCURF), so stay tuned till the end!

    Enjoy the episode!

    Timestamps:

    0:00 – Intro
    0:51 – Compass Pathways COMP360 Study Results
    3:37 – Cybin Ketamine Study
    7:14- Field Trip Uplists on the TSX And Applies To List On The NASDAQ
    11:10 – Silo Pharma Applies To Uplist on The NASDAQ
    12:11 – MagicMed to List On NASDAQ Through Acquisition
    15:16- Mydecine Expands Cultivation Capabilities for Psilocybin
    17:32- MINDCURE Completes First Stage of Manufacturing Synthetic Ibogaine

    Links:
    Compass Pathways Study Results On The Safety And Cognitive Effects Of Taking a Dose Of Psilocybin COMP360:
    https://www.globenewswire.com/news-release/2021/06/03/2241445/0/en/COMPASS-Pathways-and-Kings-College-London-publish-cognition-results-from-COMP360-psilocybin-study-in-healthy-volunteers.html

    Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics
    https://psilocybinalpha.com/news/cybin-announces-sponsorship-of-a-kernel-flow-feasibility-study-to-measure-ketamines-psychedelic-effects-on-cerebral-cortex-hemodynamics

    Field Trip Health Uplists on the TSX:
    https://www.globenewswire.com/news-release/2021/06/03/2241200/0/en/Field-Trip-Health-Ltd-to-Commence-Trading-on-the-Toronto-Stock-Exchange-on-June-7-2021.html

    FTRP Applies To Uplist On NASDAQ:
    https://stockhouse.com/news/the-market-herald-news/2021/06/08/field-trip-health-tsx-ftrp-applies-to-list-on-nasdaq-stock-market

    MagicMed Will Be Acquired by Nasdaq-listed Enveric Biosciences
    https://psilocybinalpha.com/news/magicmed-to-be-acquired-by-nasdaq-listed-company

    Health Canada Has Approved an Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms MYCO: NEO), (MYCOF: OTC) :
    https://finance.yahoo.com/news/health-canada-approves-expansion-mydecine-113000924.html

    MINDCURE, (CSE: MCUR) (OTCQB: MCURF), Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research:
    https://www.prnewswire.com/news-releases/mindcure-successfully-completes-first-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research-301304810.html

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    editing:@themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #Mydecine #FieldTrip